Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

• Published in: The New England journal of medicine Vol. 389; no. 24; pp. 2221 - 2232
• Main Authors: Lincoff, A. Michael, Brown-Frandsen, Kirstine, Colhoun, Helen M., Deanfield, John, Emerson, Scott S., Esbjerg, Sille, Hardt-Lindberg, Søren, Hovingh, G. Kees, Kahn, Steven E., Kushner, Robert F., Lingvay, Ildiko, Oral, Tugce K., Michelsen, Marie M., Plutzky, Jorge, Tornøe, Christoffer W., Ryan, Donna H.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 14.12.2023
• Subjects: Antidiabetics; Body weight; Cardiology; Cardiology General; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Cardiovascular Agents - therapeutic use; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cerebral infarction; Coronary Disease; Design; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Endocrinology; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage; Glucagon-Like Peptide-1 Receptor Agonists - adverse effects; Glucagon-Like Peptide-1 Receptor Agonists - therapeutic use; Glucagon-Like Peptides; Glucose; Heart attacks; Heart failure; Hemoglobin; Humans; Hypoglycemic Agents; Hypotheses; Hypothesis testing; Metabolism; Myocardial Infarction; Obesity; Obesity - complications; Overweight; Overweight - complications; Patients; Placebos; Prevention; Statistical analysis; Stroke

In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.